WO2008106449A1 - Incrustation de cornée à haute performance - Google Patents

Incrustation de cornée à haute performance Download PDF

Info

Publication number
WO2008106449A1
WO2008106449A1 PCT/US2008/055017 US2008055017W WO2008106449A1 WO 2008106449 A1 WO2008106449 A1 WO 2008106449A1 US 2008055017 W US2008055017 W US 2008055017W WO 2008106449 A1 WO2008106449 A1 WO 2008106449A1
Authority
WO
WIPO (PCT)
Prior art keywords
color
blue
light
lens
wavelengths
Prior art date
Application number
PCT/US2008/055017
Other languages
English (en)
Inventor
Ronald Blum
Andrew Ishak
Peter Haaland
Michael Packard
D. James Schumer
Original Assignee
High Performance Optics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by High Performance Optics, Inc. filed Critical High Performance Optics, Inc.
Publication of WO2008106449A1 publication Critical patent/WO2008106449A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/147—Implants to be inserted in the stroma for refractive correction, e.g. ring-like implants
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/024—Methods of designing ophthalmic lenses
    • G02C7/028—Special mathematical design techniques
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes
    • G02C7/046—Contact lenses having an iris pattern
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes
    • G02C7/049—Contact lenses having special fitting or structural features achieved by special materials or material structures
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
    • G02C7/104—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses having spectral characteristics for purposes other than sun-protection
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C2202/00—Generic optical aspects applicable to one or more of the subgroups of G02C7/00
    • G02C2202/16—Laminated or compound lenses

Definitions

  • Patent Application 11/761,892 filed June 12, 2007, which claims priority to U.S. Provisional Application 60/812,628 filed June 12, 2006 and is a continuation-in-part of U.S. Patent Application 11/378,317 filed March 20, 2006. All of these applications are entirely incorporated by reference.
  • chromatic aberration is caused by optical dispersion of ocular media including the cornea, intraocular lens, aqueous humour, and vitreous humour. This dispersion focuses blue light at a different image plane than light at longer wavelengths, leading to defocus of the full color image.
  • Conventional blue blocking lenses are described in U.S. Patent No. 6,158,862 to Patel et al, U.S. Patent No. 5,662,707 to Jinkerson, U.S. Patent No. 5,400,175 to Johansen, and U.S. Patent No. 4,878,748 to Johansen.
  • one common technique for blue blocking involves tinting or dyeing lenses with a blue blocking tint, such as BPI Filter Vision 450 or BPI Diamond Dye 500.
  • the tinting may be accomplished, for example, by immersing the lens in a heated tint pot containing a blue blocking dye solution for some predetermined period of time.
  • the dye solution has a yellow or amber color and thus imparts a yellow or amber tint to the lens.
  • the appearance of this yellow or amber tint may be undesirable cosmetically.
  • the tint may interfere with the normal color perception of a lens user, making it difficult, for example, to correctly perceive the color of a traffic light or sign.
  • FIG. 2 shows an example of using a dye resist to form an ophthalmic system.
  • FIG. 4 illustrates an exemplary ophthalmic system formed using an in-mold coating.
  • FIGS. 7A-7C illustrate various exemplary combinations of a blue blocking component, a color balancing component, and an ophthalmic component.
  • FIG. 11 shows the absorbance of the GENTEX E465 absorbing dye.
  • FIG. 12 shows the transmittance of a polycarbonate substrate with a dye concentration suitable for absorbing in the 430nm range.
  • FIG. 17 shows the color plot of a 106 nm layer of TiO2 on a polycarbonate substrate.
  • FIG. 20 shows the spectral transmittance of a modified AR coating suitable for color balancing a substrate having a blue absorbing dye.
  • FIG. 21 shows the color plot of a modified AR coating suitable for color balancing a substrate having a blue absorbing dye.
  • FIG. 25 shows the color plot of a substrate having a blue absorbing dye and a rear AR coating.
  • FIG. 28 shows the spectral transmittance of a substrate having a blue absorbing dye and a color balancing AR coating.
  • FIG. 31 shows the optical transmission characteristic of an exemplary film.
  • FIG. 32 shows an exemplary ophthalmic system comprising a film.
  • FIG. 33 shows an exemplary system comprising a film.
  • FIG. 34A and B show pupil diameter and pupil area, respectively, as a function of field illuminance.
  • FIG. 35 shows the transmission spectrum of a film that is doped with perylene dye where the product of concentration and path length yield about 33% transmission at about 437 nm.
  • FIG. 37 shows an exemplary transmission spectrum for a six-layer stack of Si ⁇ 2 and ZrO 2 .
  • FIG. 38 shows reference color coordinates corresponding to Munsell tiles illuminated by a prescribed illuminant in (L*, a*, b*) color space.
  • FIG. 39A shows a histogram of the color shifts for Munsell color tiles for a related filter.
  • FIG. 39B shows a color shift induced by a related blue-blocking filter.
  • FIG. 40 shows a histogram of color shifts for a perylene-dyed substrate.
  • FIG. 41 shows the transmission spectrum of a system combining dielectric stacks and perylene dye.
  • FIG. 42 shows a histogram summarizing color distortion of a device for Munsell tiles in daylight.
  • FIGS. 43A-14B show representative series of skin reflectance spectra from subjects of different races.
  • FIG. 44 shows an exemplary skin reflectance spectrum for a Caucasian subject.
  • FIG. 45 shows transmission spectra for various lenses.
  • FIG. 46 shows exemplary dyes.
  • FIG. 47 shows an ophthalmic system having a hard coat.
  • FIG. 48 shows the transmittance as a function of wavelength for a selective filter with strong absorption band around 430 nm.
  • FIG. 49A-E show embodiments of corneal inlays.
  • FIG. 49A shows a corneal inlay with micro-apertures throughout the inlay.
  • FIG. 49B shows a corneal inlay with a central zone and a peripheral region to create a pinhole effect.
  • FIG. 49C shows a corneal inlay with a curved and/or thickened peripheral region.
  • FIG. 49D shows a corneal inlay having a central zone with a plurality of pixel-like index changes.
  • FIG. 49E shows a corneal inlay having a static diffractive central zone.
  • Embodiments disclosed herein relate to an ophthalmic system that performs effective blue blocking while at the same time providing a cosmetically attractive product, normal or acceptable color perception for a user, and a high level of transmitted light for good visual acuity.
  • An ophthalmic system is provided that can provide an average transmission of 80% or better transmission of visible light, inhibit selective wavelengths of blue light ("blue blocking"), allow for the wearer's proper color vision performance, and provide a mostly color neutral appearance to an observer looking at the wearer wearing such a lens or lens system.
  • the "average transmission" of a system refers to the average transmission at wavelengths in a range, such as the visible spectrum.
  • a system also may be characterized by the "luminous transmission" of the system, which refers to an average in a wavelength range, that is weighted according to the sensitivity of the eye at each wavelength.
  • Systems described herein may use various optical coatings, films, materials, and absorbing dyes to produce the desired effect.
  • an "ophthalmic material” is one commonly used to fabricate an ophthalmic system, such as a corrective lens.
  • exemplary ophthalmic materials include glass, plastics such as CR-39, Trivex, and polycarbonate materials, though other materials may be used and are known for various ophthalmic systems.
  • An ophthalmic system may include a blue blocking component posterior to a color- balancing component. Either of the blue blocking component or the color balancing component may be, or form part of, an ophthalmic component such as a lens.
  • the posterior blue blocking component and anterior color balancing component may be distinct layers on or adjacent to or near a surface or surfaces of an ophthalmic lens.
  • Color balancing may comprise imparting, for example, a suitable proportion or concentration of blue tinting/dye, or a suitable combination of red and green tinting/dyes to the color-balancing component, such that when viewed by an external observer, the ophthalmic system as a whole has a cosmetically acceptable appearance. For example, the ophthalmic system as a whole may look clear or mostly clear.
  • An anti-absorbing coating may then be applied to the concave surface, and the front convex surface and peripheral edges of the single vision or multi-focal lens, wafer or optical pre-form may be tinted (e.g. by immersion in a heated tint pot) for color balancing.
  • the color balancing dyes will be absorbed by the peripheral edges and a portion 302 beginning at the front convex surface and extending inwardly, that was left untinted due to the earlier coating.
  • the order of the foregoing process could be reversed, i.e., the concave surface could first be masked while the remaining portion was tinted for color balancing. Then, the coating could be removed and a depth or thickness at the concave region left untinted by the masking could be tinted for blue blocking.
  • a colorless monomer 402 may be filled in and cured between the coating 403 and ophthalmic component 401.
  • the process of curing the monomer 402 will cause the color balancing in- mold coating to transfer itself to the convex surface of the ophthalmic component 401.
  • the result is a blue blocking ophthalmic system with a color balancing surface coating.
  • the in- mold coating could be, for example, an anti-reflective coating or a conventional hard coating.
  • an ophthalmic system 500 may comprise two ophthalmic components, one blue blocking and the other color balancing.
  • a first ophthalmic component 501 could be a back single vision or concave surface multi- focal lens, wafer or optical pre-form, dyed/tinted with the appropriate blue blocking tint to achieve the desired level of blue blocking.
  • a second ophthalmic component 503 could be a front single vision or convex surface multi-focal lens, wafer or optical pre-form, bonded or affixed to the back single vision or concave surface multi-focal lens, wafer or optical pre-form, for example using a UV or visible curable adhesive 502.
  • the combined functionality component may block blue light wavelengths and reflect some green and red wavelengths as well, thus neutralizing the blue and eliminating the appearance of a dominant color in the lens.
  • the combined functionality component 803 may be arranged on or adjacent to either the anterior or the posterior surface of a clear ophthalmic lens 802.
  • the ophthalmic lens 800 may further include an AR component 801 on or adjacent to either the anterior or the posterior surface of the clear ophthalmic lens 802.
  • FIG. 9 shows a CIE plot indicating the observed colors corresponding to various CIE coordinates.
  • a reference point 900 indicates the coordinates (0.33, 0.33).
  • the central region of the plot typically is designated as "white,” some light having CIE coordinates in this region can appear slightly tinted to a viewer. For example, light having CIE coordinates of (0.4, 0.4) will appear yellow to an observer.
  • (0.33, 0.33) light i.e., white light
  • the CIE plot shown in FIG. 9 will be used herein as a reference to show the color shifts observed with various systems, though the labeled regions will be omitted for clarity.
  • Absorbing dyes may be included in the substrate material of an ophthalmic lens by injection molding the dye into the substrate material to produce lenses with specific light transmission and absorption properties. These dye materials can absorb at the fundamental peak wavelength of the dye or at shorter resonance wavelengths due to the presence of a Soret band typically found in porphyrin materials.
  • Exemplary ophthalmic materials include various glasses and polymers such as CR-39 ® , TRTVEX ® , polycarbonate, polymethylmethacrylate, silicone, and fluoropolymers, though other materials may be used and are known for various ophthalmic systems.
  • GENTEX dye material E465 transmittance and absorbance is shown in FIGS. 10-11.
  • Air farest from the user's eye
  • Front convex lens coating Absorbing ophthalmic lens substrate
  • rear concave anti-reflection coating Air (closest to the user's eye).
  • the ophthalmic system may limit transmission of the blue wavelengths within the above-defined ranges to substantially 50% of incident wavelengths. In other embodiments, the ophthalmic system may limit transmission of the blue wavelengths within the above-defined ranges to substantially 40% of incident wavelengths. In still other embodiments, the ophthalmic system may limit transmission of the blue wavelengths within the above-defined ranges to substantially 30% of incident wavelengths. In still other embodiments, the ophthalmic system may limit transmission of the blue wavelengths within the above-defined ranges to substantially 20% of incident wavelengths. In still other embodiments, the ophthalmic system may limit transmission of the blue wavelengths within the above-defined ranges to substantially 10% of incident wavelengths.
  • the ophthalmic system selectively inhibits light within a range of blue light wavelengths.
  • the inhibited range of blue light wavelengths can be any range within, including the endpoints of, 400 nm to 500 nm.
  • the inhibited wavelengths can be, for example, 400 to 500 nm, 400 to 475 nm, 400 nm to 470 nm, 400 to 450 nm, 400 to 460 nm, 410 to 450 nm, 420 to 440 nm, or about 430 nm.
  • FIG. 33 shows an exemplary system 3300, such as an automotive windshield.
  • a film 3301 may be incorporated into the system 3300, where it is sandwiched between layers of base material 3302, 3303.
  • the base material 3302, 3303 may be windshield glass as is commonly used. It will be understood that in various other systems, including visual, display, ophthalmic, and other systems, different base materials may be used without departing from the scope of the present invention.
  • a system may be operated in an environment where the relevant emitted visible light has a very specific spectrum.
  • the ophthalmic filter according to Pratt reduces scotopic sensitivity by 83.6% of its unfiltered value, an attenuation that will both degrade night vision and stimulate pupil dilation according to equation 1.1.
  • the device described by Mainster reduces scotopic flux by 22.5%, which is less severe than the Pratt device but still significant.
  • a film as disclosed herein may partially attenuates violet and blue light using absorptive or reflective ophthalmic elements while reducing the scotopic illuminance by no more than 15% of its unfiltered value. Surprisingly, such systems were found to selectively inhibit a desired region of blue light, while having little to no effect on photopic and scotopic vision.
  • a film that selectively inhibits blue light is described as inhibiting an amount of light measured relative to the base system incorporating the film.
  • an ophthalmic system may use a polycarbonate or other similar base for a lens. Materials typically used for such a base may inhibit a various amount of light at visible wavelengths. If a blue-blocking film is added to the system, it may selectively inhibit 5%, 10%, 20%, 30%, 40%, and/or 50% of all blue wavelengths, as measured relative to the amount of light that would be transmitted at the same wavelength(s) in the absence of the film.
  • the methods and devices disclosed herein may minimize, and preferably eliminate, the shift in color perception that results from blue-blocking.
  • the color perceived by the human visual system results from neural processing of light signals that fall on retinal pigments with different spectral response characteristics.
  • a color space is constructed by integrating the product of three wavelength- dependent color matching functions with the spectral irradiance. The result is three numbers that characterize the perceived color.
  • a uniform (L*, a*, b*) color space which has been established by the Commission Internationale de L'eclairage (CIE), may be used to characterize perceived colors, although similar calculations based on alternative color standards are familiar to those practiced in the art of color science and may also be used.
  • CIE Commission Internationale de L'eclairage
  • the (L*, a*, b*) color space defines brightness on the L* axis and color within the plane defined by the a* and b* axes.
  • a uniform color space such as that defined by this CIE standard may be preferred for computational and comparative applications, since the Cartesian distances of the space are proportional to the magnitude of perceived color difference between two objects.
  • the use of uniform color spaces generally is recognized in the art, such as described in Wyszecki and Stiles, Color Science: Concepts and Methods, Quantitative Data and Formulae (Wiley: New York) 1982.
  • An optical design according to the methods and systems described herein may use a palette of spectra that describe the visual environment.
  • a non-limiting example of this is the Munsell matte color palette, which is comprised of 1,269 color tiles that have been established by psychophysical experiments to be just noticeably different from each other.
  • the spectral irradiance of these tiles is measured under standard illumination conditions.
  • the array of color coordinates corresponding to each of these tiles illuminated by a D65 daylight illuminant in (L*, a*, b*) color space is the reference for color distortion and is shown in FIG. 38.
  • the spectral irradiance of the color tiles is then modulated by a blue-blocking filter and a new set of color coordinates is computed.
  • the color shift induced by the Mainster blue-blocking filter has a minimum value of 6, an average of 19, a maximum of 34, and a standard deviation of 6 JNDs.
  • a combination of reflective and absorptive elements may filter harmful blue photons while maintaining relatively high luminous transmission. This may allow a system to avoid or reduce pupil dilation, preserve or prevent damage to night vision, and reduce color distortion.
  • An example of this approach combines the dielectric stacks shown in FIG. 37 with the perylene dye of FIG. 35, resulting in the transmission spectrum shown in FIG. 41. The device was observed to have a photopic transmission of 97.5%, scotopic transmission of 93.2%, and an average color shift of 11 JNDs. The histogram summarizing color distortion of this device for the Munsell tiles in daylight is shown in FIG. 42.
  • an illuminant may be filtered to reduce but not eliminate the flux of blue light to the retina. This may be accomplished with absorptive or reflective elements between the field of view and the source of illumination using the principles described herein.
  • an architectural window may be covered with a film that contains perylene so that the transmission spectrum of the window matches that shown in FIG. 35.
  • Such a filter typically would not induce pupil dilation when compared to an uncoated window, nor would it cause appreciable color shifts when external daylight passes through it.
  • Blue filters may be used on artificial illuminants such as fluorescent, incandescent, arc, flash, and diode lamps, displays, and the like.
  • the filtering and color balancing dyes may be incorporated into a hard coating and/or an associated primer coating which promotes adhesion of the hard coating to the lens material.
  • a primer coat and associated hard coat are often added to the top of a spectacle lens or other ophthalmic system at the end of the manufacturing process to provide additional durability and scratch resistance for the final product.
  • the hard coat typically is an outer-most layer of the system, and may be placed on the front, back, or both the front and back surfaces of the system.
  • both a blue blocking dye and a color balancing dye may be included in the primer coating 1802. Both the blue blocking and color balancing dyes also may be included in the hard coating 1803. The dyes need not be included in the same coating layer.
  • a blue blocking dye may be included in the hard coating 1803, and a color balancing dye included in the primer coating 1802.
  • the color balancing dye may be included in the hard coating 1803 and the blue blocking dye in the primer coating 1802.
  • Primer and hard coats may be deposited using methods known in the art, including spin-coating, dip-coating, spray-coating, evaporation, sputtering, and chemical vapor deposition.
  • the blue blocking and/or color balancing dyes to be included in each layer may be deposited at the same time as the layer, such as where a dye is dissolved in a liquid coating material and the resulting mixture applied to the system.
  • the dyes also may be deposited in a separate process or sub-process, such as where a dye is sprayed onto a surface before the coat is cured or dried or applied.
  • Such a system functions to selectively filter harmful invisible and visible light while having minimal effect on photopic vision, scotopic vision, color vision, and/or circadian rhythms while maintaining acceptable or even improved contrast sensitivity.
  • the end residual color of the device to which the selective filter is applied is mostly colorless, and in other embodiments where a mostly clear residual color is not required the residual color can be yellowish.
  • the yellowness of the selective filter is unobjectionable to the subjective individual wearer. Yellowness can be measured quantitatively using a yellowness index such as ASTM E313-05.
  • the selective filter has a yellowness index that is no more than 50, 40, 35, 30, 25, 23, 20, 15, 10, 9, 7, or 5.
  • the system could include selective light wavelength filtering embodiments such as: windows, automotive windshields, light bulbs, flash bulbs, fluorescent lighting, LED lighting, television, computer monitors, etc. Any light that impacts the retina can be selectively filtered by the system.
  • the system can be enabled, by way of example only, a film comprising a selective filtering dye or pigment, a dye or pigment component added after a substrate is fabricated, a dye component that is integral with the fabrication or formulation of the substrate material, synthetic or non-synthetic pigment such as melanin, lutein, or zeaxanthin, selective filtering dye or pigment provided as a visibility tint (having one or more colors) as in a contact lens, selective filtering dye or pigment provided in an ophthalmic scratch resistant coating (hard coat), selective filtering dye or pigment provided in an ophthalmic anti- reflective coat, selective light wave length filtering dye or pigment provided in a hydrophobic coating, an interference filter, selective light wavelength filter, selective light wavelength filtering dye or pigment provided in a photochromic lens, or
  • the selective filter can be: imbibed, injected, impregnated, added to the raw materials of the substrate, added to the resin prior to polymerization, layered within in the optical lens by way of a film comprising the selective filter dye or pigments.
  • the system may utilize a proper concentration of a dye and or pigment such as, by way of example only, perylene, porphrin or their derivatives.
  • a dye and or pigment such as, by way of example only, perylene, porphrin or their derivatives.
  • the transmission level can be controlled by dye concentration.
  • Other dye chemistries allow adjustment of the absorption peak positions.
  • Perylene at appropriate concentration levels in an appropriate base material provides balance in photopic, scotopic, circadian, and phototoxicity ratios while maintaining a mostly colorless appearance:
  • perylene based dyes or pigments are exemplary dyes.
  • the dye may be formulated such that it is bonded molecularly or chemically to the substrate or a coating that is applied to the substrate such that the dye does not leach out.
  • applications of this would be for use with contact lenses, IOLs, corneal in-lays, corneal on-lays, etc.
  • Selective filters can be combined to hinder other target wavelengths as science discovers other visible light wavelength hazards.
  • the dye or pigment can be imparted into the contact lens by way of example only, by imbibing, so that it is located within a central 10 mm diameter or less circle of the contact lens, preferably within 6 - 8 mm diameter of the center of the contact lens coinciding with the pupil of the wearer.
  • the dye or pigment concentration which provides selective light wavelength filtering is increased to a level that provides the wearer with an increase in contrast sensitivity (as oppose to without wearing the contact lens) and without compromising in any meaningful way (one or more, or all of) the wearer's photopic vision, scotopic vision, color vision, or circadian rhythms.
  • the dye or pigment is provided that causes a yellowish tint that it is located over the central 5 - 7 mm diameter of the contact lens and wherein a second color tint is added peripherally to that of the central tint.
  • the dye concentration which provides selective light wavelength filtering is increased to a level that provides the wearer very good contrast sensitivity and once again without compromising in any meaningful way (one or more, or all of) the wearer's photopic vision, scotopic vision, color vision, or circadian rhythms.
  • the dye or pigment is provided such that it is located over the full diameter of the contact lens from approximately one edge to the other edge.
  • the dye is formulated in such a way to chemically bond to the inlay substrate material thus ensuring it will not leach out in the surrounding corneal tissue.
  • Methods for providing a chemical hook that allow for this bonding are well known within the chemical and polymer industries.
  • a spectacle lens includes a selective light wave length filter comprising a dye having perylene wherein the dye's formulation provides a spectacle lens that has a mostly colorless appearance. And furthermore that provides the wearer with improved contrast sensitivity without compromising in any meaningful way (one or more, or all of) the wearer's photopic vision, scotopic vision, color vision, or circadian rhythms.
  • the dye or pigment is imparted within a film that is located within or on the surface of the spectacle lens.
  • the system can be a corneal inlay.
  • the corneal inlay can provide protection to a plurality of ocular structures within the eye while maintaining acceptable color cosmetics, color perception, overall light transmission, photopic vision, scotopic vision, color vision, and/or cirdadian rhythms.
  • the corneal inlay can provide proper corneal metabolism.
  • the corneal inlay can also include a pinhole effect to improve clear near-point vision and increase depth of focus.
  • the corneal inlay can also correct refractive errors including, but not limited to, higher order aberration, lower order aberration, myopia, hyperopia, astigmatism, and/or presbyopia.
  • One or more blue-blocking dyes can be added to the bio-compatible material during or after processing by way of any technique known in the art of optical manufacturing.
  • a dye can be incorporated directly into the substrate, added to a polymeric coating, imbibed into the inlay, incorporated in a laminated structure that includes a dye-impregnated layer, or as a composite material with dye-impregnated microparticles.
  • the dye should be prevented from leaching out into the surrounding cornea.
  • the dye can be covalently bound to the substrate material.
  • the dye can be imbibed, dispersed, or dissolved in the substrate and encapsulated in a cross-linked polymer to inhibit diffusion of the dye out of the corneal inlay.
  • a sealing layer can be placed on the corneal implant.
  • a sealing layer can be, for example, a sealer-like coating, a thin polymer layer, or a layer that is laminated within the corneal inlay comprising the dye(s).
  • the corneal inlay further comprises a UV-inhibiting material, e.g., a UV-blocking dye.
  • a UV-inhibiting material e.g., a UV-blocking dye.
  • UV-inhibiting materials are well-known in the art and are used in many ophthalmic lens applications.
  • an ultraviolet- inhibiting material blocks at least about 90%, preferably at least about 95%, or at least about 99% of light at wavelengths of less than about 400 nm, preferably about 280 nm to about 400 nm or increments therein, such as about 280 nm to about 315 nm.
  • the corneal inlay can provide a pinhole effect to enhance the depth perception and near-point focus of the wearer.
  • the pinhole effect can be created by any ophthalmic system described herein, e.g., a spectacle lens, contact lens, intra-ocular lens, corneal inlay, and corneal onlay.
  • the pinhole effect can be created by providing a central zone, which allows a high transmission of visible light, and a peripheral region, which limits the transmission of visible light.
  • the central zone and peripheral region act as a static shutter or lens stop.
  • Static means fixed, i.e., not dynamic.
  • the pinhole effect can be created by, for example, an opaque, frosted, crazed, or defocused peripheral region with a central transmissive, un-frosted, un-crazed, or focused zone (FIG. 49B).
  • the diameter of the central zone is preferably about 2.5 mm to about 1 mm or increments therein, or about 1.5 mm.
  • the central zone can be circular, or it can be any other shape in the interior of the inlay.
  • the central zone can be a symmetrical, asymmetrical, geometric, curved, or irregular shape.
  • the central zone is circular and is centered in the inlay.
  • the pinhole effect can increase depth of focus and enhance near- focus vision for a presbyopic or emerging-presbyopic individual.
  • a pinhole corneal inlay can be implanted in one or both eyes of a patient.
  • a pinhole corneal inlay is implanted in a monocular manner, i.e., in only one eye of a patient.
  • the pinhole corneal inlay is preferably implanted into the non-dominant eye.
  • a corneal inlay without a pinhole effect, such as a blue-blocking corneal inlay described herein, can be implanted in the dominant eye.
  • both eyes receive a corneal inlay comprising the blue-blocking and/or UV-blocking features described herein.
  • the central zone includes a blue- blocking component.
  • the central zone includes one or more dyes that selectively inhibit light within a range of blue light wavelengths as described above.
  • This embodiment surprisingly both protects the retina from harmful blue light wavelengths while also enhancing depth perception.
  • the pinhole effect depends on the difference in contrast between the central zone and the peripheral region.
  • One might predict that including a dye in the central zone would decrease the contrast differential between the central zone and the peripheral region and thus eliminate the pinhole effect and its accompanying enhancement of depth perception.
  • the inventors have discovered that even with the blue-blocking dye, the contrast differential can be sufficiently maintained to achieve the pinhole effect.
  • the central zone and the peripheral region can be designed to maintain a contrast differential of at least about 60%, at least about 65%, at least about 70%, at least about 80%, or at least about 90%.
  • the contrast differential is about 60% to about 80% or increments therein, such as about 60% to about 65%, and about 70% to about 80%.
  • the transmission of visible light through the center zone can be, for example, about 80% to about 95% or increments therein, about 85% to about 95%, or about 90%.
  • the transmission of visible light through the peripheral region can be, for example, about 15% to about 30% or increments therein, about 20% to about 30%, or about 20% to about 25%.
  • the transmission of visible light can be measured by, e.g., average transmission or preferably by luminous transmission.
  • Proper corneal metabolism can be achieved by selecting bio-compatible materials, properly positioning the corneal inlay, and/or providing micro-apertures as described below.
  • the inventive corneal inlay can be made of various bio-compatible materials including, but not limited to, a non-hydrogel, microporous, ophthalmic perfluoropolyether material; a polyvinylidene fluoride material; or any other suitable plastic material known in the field of ophthalmics.
  • the corneal inlay can include a plurality of micro-apertures (FIG. 49A).
  • the micro- apertures can be created during or after processing of the bio-compatible material.
  • the micro- apertures allow for proper corneal metabolism including fluids, nutrients, solutes, and extracellular transport.
  • the micro-apertures can be formed throughout the entirety of the corneal inlay, or any portion thereof.
  • the micro-apertures can be formed in the peripheral region and/or in the central zone. In one embodiment, the micro-apertures are formed only in the peripheral region.
  • the corneal inlay can be implanted into the eye by any known methodology and/or the methodology described herein.
  • the cornea can be prepared to receive the corneal inlay by sectioning the cornea to create a corneal flap having the proper thickness, diameter, and location relative to the pupil and the limbus.
  • the corneal flap can be created by, e.g., a mechanical microkeratome or femtosecond laser. Procedures for creating a corneal flap are well-known in the art and are used with LASIK procedures as well as other lamellar corneal surgical procedures. [0193] In one embodiment, the flap is not removed from the cornea, but is folded out of the way as the corneal inlay is properly positioned into place.
  • the corneal flap is unfolded and positioned over the corneal inlay.
  • the diameter of the corneal flap can be larger than that of the corneal inlay thus allowing for the cornea to seal and heal around the periphery of the corneal inlay.
  • the method for implanting the corneal inlay can further include a step of performing Laser-Assisted in situ Keratomileusis (LASIK) to alter the shape of the cornea.
  • LASIK Laser-Assisted in situ Keratomileusis
  • a LASIK procedure can be performed to alter, improve, and/or correct a refractive error of the patient.
  • a LASIK procedure can also be used to sculpt a more defined and deeper recess in the cornea to facilitate positioning of the corneal inlay.
  • the corneal inlay can be positioned within a recess, and the corneal flap can be repositioned over the corneal inlay. In this way, a thicker corneal inlay can be implanted.
  • the corneal inlay may correct a lower order aberration or a higher order aberration as described below. Any of these corrections includes a complete correction of, or any improvement to, the refractive error of the wearer.
  • the corneal inlay can correct a refractive error such as myopia, hyperopia, or astigmatism.
  • the correction of refractive error can be achieved by one or more features including, but not limited to, curving the peripheral region of the corneal inlay, thickening the peripheral region of the corneal inlay, altering the diameter of the corneal inlay (FIG. 49C).
  • the corneal inlay can cause refractive changes and/or reshape the external corneal curvature.
  • the corneal inlay can correct a refractive error, including presbyopia, by way of diffraction.
  • the corneal inlay includes a diffractive design pattern (FIG. 49E) on an external surface of the corneal inlay or embedded in the interior of the corneal inlay.
  • the central zone of the corneal inlay includes a plurality of pixel-like index of refractive changes (FIG. 49D) to impart an index change.
  • Index changes can provide spherical refractive changes and/or correct for higher order aberration.
  • Higher order aberrations are refractive error aberrations other than myopia, hyperopia, regular astigmatism, and presbyopia.
  • One embodiment is a method of correcting for higher order aberration by performing a wavefront measurement of the wearer, then correcting the wavefront measurement by implanting a corneal inlay including a plurality of index changes.
  • This corneal inlay can be created, e.g., by curing the polymer of the corneal inlay (or a layer of modifiable polymer material affixed to the corneal inlay) to provide a predictable and desired localized index of refraction changes.
  • the index changes can be imparted in situ by a final cure of the corneal inlay (either of the entire material structure, or a layer of material that is present on, or located inside of, the corneal inlay) after the corneal inlay is implanted within the cornea.
  • the final cure can be performed by, e.g., a specified and targeted light radiation cure, occurring almost simultaneously in a mostly closed loop manner to refine and perfect the higher order aberration correction.
  • a method of correcting higher order aberration can include performing an iterative wavefront analysis while curing the corneal inlay to impart an index change.
  • the wavefront analysis and in situ curing method described above can also be used to correct for lower order aberrations such as myopia, hyperopia, regular astigmatism, and presbyopia.
  • Wavefront analysis and photo-curing polymers using visible and non-visible light sources are both well-known in the art.
  • a wavefront aberrometer an auto-refractor, and/or a manual refractor can be used.
  • the methods can include one, two, or more refining steps achieve the final optical correction of the corneal inlay when using the inventive closed loop method previously described.
  • any one or more of the above-described features inhibiting UV light; inhibiting a range of blue light wavelengths; static shuttering; correcting refractive error; correcting lower order aberration including myopia, hyperopia, regular astigmatism, and presbyopia; and correcting higher order aberration — can be used with any embodiment described herein.
  • Example 1 A polycarbonate lens having an integral film with varying concentrations of blue-blocking dye was fabricated and the transmission spectrum of each lens was measured as shown in FIG. 45. Perylene concentrations of 35, 15, 7.6, and 3.8 ppm (weight basis) at a lens thickness of 2.2 mm were used. Various metrics calculated for each lens are shown in Table IV, with references corresponding to the reference numerals in FIG. 45. Since the selective absorbance of light depends primarily on the product of the dye concentration and coating thickness according to Beer's law, it is believed that comparable results are achievable using a hard coat and/or primer coat in conjunction with or instead of a film.
  • all the lenses described in Table IV and FIG. 45 include a UV dye typically used in ophthalmic lens systems to inhibit UV wavelengths below 380 nm.
  • the photopic ratio describes normal vision, and is calculated as the integral of the filter transmission spectrum and V ⁇ (photopic visual sensitivity) divided by the integral of unfiltered light and this same sensitivity curve.
  • the scotopic ratio describes vision in dim lighting conditions, and is calculated as the integral of the filter transmission spectrum and V' ⁇ (scotopic visual sensitivity) divided by the integral of unfiltered light and this same sensitivity curve.
  • the circadian ratio describes the effect of light on circadian rhythms, and is calculated as the integral of the filter transmission spectrum and M' ⁇ (melatonin suppression sensitivity) divided by the integral of unfiltered light and this same sensitivity curve.
  • the phototoxicity ratio describes damage to the eye caused by exposure to high-energy light, and is calculated as the integral of the filter transmission and the B ⁇ (phakic UV-blue phototoxicity) divided by the integral of unfiltered light and this same sensitivity curve.
  • Response functions used to calculate these values correspond to those disclosed in Mainster and Sparrow, "How Much Blue Light Should an IOL Transmit?" Br. J. Ophthalmol, 2003, v. 87, pp. 1523-29, Mainster, "Intraocular Lenses Should Block UV Radiation and Violet but not Blue Light," Arch.
  • a system may selectively inhibit blue light, specifically light in the 400 nm - 460 nm region, while still providing a photopic luminous transmission of at least about 85% and a phototoxicity ration of less than about 80%, more preferably less than about 70%, more preferably less than about 60%, and more preferably less than about 50%.
  • a photopic luminous transmission of up to 95% or more also may be achievable using the techniques described herein.
  • Example 2 Nine patients were tested for contrast sensitivity using dye concentrations of IX and 2X against a clear filter as a control. 7 of the 9 patients showed overall improved contrast sensitivity according to the Functional Acuity Contrast Test (FACT). See Table VI:

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Mathematical Physics (AREA)
  • Eyeglasses (AREA)
  • Prostheses (AREA)

Abstract

L'invention concerne une incrustation de cornée qui protège les structures oculaires contre les longueurs d'onde de lumière nuisibles tout en maintenant une esthétique des couleurs, une perception des couleurs, une transmission de lumière globale, une vision photopique, une vision scotopique, une vision des couleurs et/ou des rythmes circadiens acceptables. L'incrustation de cornée peut également comprendre un effet de trou d'épingle pour augmenter la profondeur du foyer. Dans certains modes de réalisation, l'incrustation de cornée peut également corriger les erreurs de réfraction comprenant, sans s'y limiter, l'aberration d'ordre supérieur, l'aberration d'ordre inférieur, la myopie, l'hypermétropie, l'astigmatisme et/ou la presbytie.
PCT/US2008/055017 2007-02-26 2008-02-26 Incrustation de cornée à haute performance WO2008106449A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90332407P 2007-02-26 2007-02-26
US60/903,324 2007-02-26
US90620507P 2007-03-12 2007-03-12
US60/906,205 2007-03-12

Publications (1)

Publication Number Publication Date
WO2008106449A1 true WO2008106449A1 (fr) 2008-09-04

Family

ID=39721585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055017 WO2008106449A1 (fr) 2007-02-26 2008-02-26 Incrustation de cornée à haute performance

Country Status (1)

Country Link
WO (1) WO2008106449A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9063349B2 (en) 2006-03-20 2015-06-23 High Performance Optics, Inc. High performance selective light wavelength filtering
US9377569B2 (en) 2006-03-20 2016-06-28 High Performance Optics, Inc. Photochromic ophthalmic systems that selectively filter specific blue light wavelengths
US9683102B2 (en) 2014-05-05 2017-06-20 Frontier Scientific, Inc. Photo-stable and thermally-stable dye compounds for selective blue light filtered optic
US9798163B2 (en) 2013-05-05 2017-10-24 High Performance Optics, Inc. Selective wavelength filtering with reduced overall light transmission
EP3232253A3 (fr) * 2016-04-14 2018-01-03 Johnson & Johnson Vision Care Inc. Procédés et appareil destinés à améliorer des concentrations d'oxygène pour dispositifs ophtalmiques
EP3232252A3 (fr) * 2016-04-14 2018-01-10 Johnson & Johnson Vision Care Inc. Procédés et appareil destinés à améliorer des concentrations d'oxygène pour dispositifs ophtalmiques avancés
US9927635B2 (en) 2006-03-20 2018-03-27 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US10007039B2 (en) 2012-09-26 2018-06-26 8797625 Canada Inc. Multilayer optical interference filter
US10495795B2 (en) 2014-05-23 2019-12-03 Eyesafe, Llc Light emission reducing compounds for electronic devices
US10642087B2 (en) 2014-05-23 2020-05-05 Eyesafe, Llc Light emission reducing compounds for electronic devices
US10955697B2 (en) 2018-11-28 2021-03-23 Eyesafe Inc. Light emission modification
US10971660B2 (en) 2019-08-09 2021-04-06 Eyesafe Inc. White LED light source and method of making same
WO2021122530A1 (fr) * 2019-12-16 2021-06-24 Essilor International Procédés de conception d'une lentille ophtalmique teintée et de lentilles ophtalmiques teintées, et lentille ophtalmique teintée correspondante
US11126033B2 (en) 2018-11-28 2021-09-21 Eyesafe Inc. Backlight unit with emission modification
US11592701B2 (en) 2018-11-28 2023-02-28 Eyesafe Inc. Backlight unit with emission modification
WO2023106209A1 (fr) * 2021-12-06 2023-06-15 株式会社ニコン・エシロール Stratifié, procédé de production pour verre de lunettes avec couche protectrice, et procédé de production pour verre de lunettes
US11701315B2 (en) 2006-03-20 2023-07-18 High Performance Optics, Inc. High energy visible light filter systems with yellowness index values
US11810532B2 (en) 2018-11-28 2023-11-07 Eyesafe Inc. Systems for monitoring and regulating harmful blue light exposure from digital devices

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521765A (en) * 1994-07-07 1996-05-28 The Boc Group, Inc. Electrically-conductive, contrast-selectable, contrast-improving filter
US20040084790A1 (en) * 1999-07-02 2004-05-06 Blum Ronald D. Method of manufacturing an electro-active lens
US20060099148A1 (en) * 2004-01-15 2006-05-11 Mount Sinai School Of Medicine Methods and compositions for imaging
US20060126019A1 (en) * 2004-12-10 2006-06-15 Junzhong Liang Methods and systems for wavefront analysis
US20060228725A1 (en) * 2002-01-24 2006-10-12 Biodesy Llc Method using a nonlinear optical technique for detection of interactions involving a conformational change
US20060235428A1 (en) * 2005-04-14 2006-10-19 Silvestrini Thomas A Ocular inlay with locator
US20070034833A1 (en) * 2004-01-15 2007-02-15 Nanosys, Inc. Nanocrystal doped matrixes
US20070035240A1 (en) * 2005-08-09 2007-02-15 Au Optronics Corporation White organic light-emitting diode

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521765A (en) * 1994-07-07 1996-05-28 The Boc Group, Inc. Electrically-conductive, contrast-selectable, contrast-improving filter
US20040084790A1 (en) * 1999-07-02 2004-05-06 Blum Ronald D. Method of manufacturing an electro-active lens
US20060228725A1 (en) * 2002-01-24 2006-10-12 Biodesy Llc Method using a nonlinear optical technique for detection of interactions involving a conformational change
US20060099148A1 (en) * 2004-01-15 2006-05-11 Mount Sinai School Of Medicine Methods and compositions for imaging
US20070034833A1 (en) * 2004-01-15 2007-02-15 Nanosys, Inc. Nanocrystal doped matrixes
US20060126019A1 (en) * 2004-12-10 2006-06-15 Junzhong Liang Methods and systems for wavefront analysis
US20060235428A1 (en) * 2005-04-14 2006-10-19 Silvestrini Thomas A Ocular inlay with locator
US20070035240A1 (en) * 2005-08-09 2007-02-15 Au Optronics Corporation White organic light-emitting diode

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11701315B2 (en) 2006-03-20 2023-07-18 High Performance Optics, Inc. High energy visible light filter systems with yellowness index values
US9377569B2 (en) 2006-03-20 2016-06-28 High Performance Optics, Inc. Photochromic ophthalmic systems that selectively filter specific blue light wavelengths
US9063349B2 (en) 2006-03-20 2015-06-23 High Performance Optics, Inc. High performance selective light wavelength filtering
US10551637B2 (en) 2006-03-20 2020-02-04 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US9927635B2 (en) 2006-03-20 2018-03-27 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US11774783B2 (en) 2006-03-20 2023-10-03 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US10007039B2 (en) 2012-09-26 2018-06-26 8797625 Canada Inc. Multilayer optical interference filter
US9798163B2 (en) 2013-05-05 2017-10-24 High Performance Optics, Inc. Selective wavelength filtering with reduced overall light transmission
US9683102B2 (en) 2014-05-05 2017-06-20 Frontier Scientific, Inc. Photo-stable and thermally-stable dye compounds for selective blue light filtered optic
US11947209B2 (en) 2014-05-23 2024-04-02 Eyesafe Inc. Light emission reducing compounds for electronic devices
US10901125B2 (en) 2014-05-23 2021-01-26 Eyesafe, Llc Light emission reducing compounds for electronic devices
US10871671B2 (en) 2014-05-23 2020-12-22 Eyesafe, Llc Light emission reducing compounds for electronic devices
US10642087B2 (en) 2014-05-23 2020-05-05 Eyesafe, Llc Light emission reducing compounds for electronic devices
US10495795B2 (en) 2014-05-23 2019-12-03 Eyesafe, Llc Light emission reducing compounds for electronic devices
US9964780B2 (en) 2016-04-14 2018-05-08 Johnson & Johnson Vision Care, Inc. Methods and apparatus to enhance oxygen concentrations for advanced ophthalmic devices
EP3422085A1 (fr) * 2016-04-14 2019-01-02 Johnson & Johnson Vision Care Inc. Procédés et appareil destinés à améliorer des concentrations d'oxygène pour dispositifs ophtalmiques avancés
US10775645B2 (en) 2016-04-14 2020-09-15 Johnson & Johnson Vision Care, Inc. Methods and apparatus to enhance oxygen concentrations for advanced ophthalmic devices
US10459250B2 (en) 2016-04-14 2019-10-29 Johnson & Johnson Vision Care, Inc. Methods and apparatus to enhance oxygen concentrations for advanced ophthalmic devices
EP3425444A1 (fr) * 2016-04-14 2019-01-09 Johnson & Johnson Vision Care Inc. Procédés et appareil destinés à améliorer des concentrations d'oxygène pour dispositifs ophtalmiques avancés
US10473954B2 (en) 2016-04-14 2019-11-12 Johnson & Johnson Vision Care, Inc. Methods and apparatus to enhance oxygen concentrations for advanced ophthalmic devices
EP3232253A3 (fr) * 2016-04-14 2018-01-03 Johnson & Johnson Vision Care Inc. Procédés et appareil destinés à améliorer des concentrations d'oxygène pour dispositifs ophtalmiques
EP3232252A3 (fr) * 2016-04-14 2018-01-10 Johnson & Johnson Vision Care Inc. Procédés et appareil destinés à améliorer des concentrations d'oxygène pour dispositifs ophtalmiques avancés
US10955697B2 (en) 2018-11-28 2021-03-23 Eyesafe Inc. Light emission modification
US11126033B2 (en) 2018-11-28 2021-09-21 Eyesafe Inc. Backlight unit with emission modification
US11347099B2 (en) 2018-11-28 2022-05-31 Eyesafe Inc. Light management filter and related software
US11592701B2 (en) 2018-11-28 2023-02-28 Eyesafe Inc. Backlight unit with emission modification
US11810532B2 (en) 2018-11-28 2023-11-07 Eyesafe Inc. Systems for monitoring and regulating harmful blue light exposure from digital devices
US10998471B2 (en) 2019-08-09 2021-05-04 Eyesafe Inc. White LED light source and method of making same
US10971660B2 (en) 2019-08-09 2021-04-06 Eyesafe Inc. White LED light source and method of making same
WO2021122530A1 (fr) * 2019-12-16 2021-06-24 Essilor International Procédés de conception d'une lentille ophtalmique teintée et de lentilles ophtalmiques teintées, et lentille ophtalmique teintée correspondante
WO2023106209A1 (fr) * 2021-12-06 2023-06-15 株式会社ニコン・エシロール Stratifié, procédé de production pour verre de lunettes avec couche protectrice, et procédé de production pour verre de lunettes

Similar Documents

Publication Publication Date Title
US11774783B2 (en) High performance selective light wavelength filtering providing improved contrast sensitivity
US11701315B2 (en) High energy visible light filter systems with yellowness index values
US9063349B2 (en) High performance selective light wavelength filtering
US8360574B2 (en) High performance selective light wavelength filtering providing improved contrast sensitivity
CA2670789C (fr) Filtrage selectif haute performance de longueurs d'ondes lumineuses permettant d'obtenir une meilleure sensibilite au contraste
US9377569B2 (en) Photochromic ophthalmic systems that selectively filter specific blue light wavelengths
AU2010229849B2 (en) Photochromic ophthalmic systems that selectively filter specific blue light wavelengths
CN111292615B (zh) 提供改进的对比灵敏度的高性能选择性光波长过滤
WO2008106449A1 (fr) Incrustation de cornée à haute performance
CA2924278C (fr) Filtrage selectif haute performance de longueurs d'ondes lumineuses permettant d'obtenir une meilleure sensibilite au contraste

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08730757

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08730757

Country of ref document: EP

Kind code of ref document: A1